Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Alpha 2 Interferon + Bevacizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alpha 2 Interferon||Roferon-A||AlferonIinterferon alfa 2a|interferon alpha 2a||Roferon-A (alpha 2 Interferon) is a recombinant form of human interferon alfa-2a, which binds to its receptor, activating anti-viral, anti-proliferative, anti-cancer, and immune modulating downstream effectors (NCI Drug Dictionary).|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 36||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|VHL inact mut||renal cell carcinoma||predicted - sensitive||Alpha 2 Interferon + Bevacizumab||Clinical Study - Cohort||Actionable||In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy, including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).||16827904|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|